Company intelligence / Profile preview
Taro
Haifa, Israel
- Ownership
- Private
- Employees
- ~1000
- Development stage
- Other
01
Overview
Taro has a substantial commercial portfolio of over 180 prescription and OTC drugs, including small molecule generics and some proprietary products. Recent clinical results are not public as it focuses on commercialized generics and branded molecules[3][1][8].
- Therapeutic areas
- Infectious DiseasesDermatologyPulmonologyCardiovascularOtherNeurology
- Modalities
- Small moleculeProtein
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
Request access →03
Partnerships
Sun Pharmaceutical Industries (acquirer, integration partner)Medicis (licensed Topicort, A/T/S, Ovide, Primsol)Various distributors and supply partnerships globally
Beyond the preview
Go deeper on Taro.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Taro.